MGI Pharma purchases Hexalen from MedImmune

MOGN will pay MEDI $7.2 million over 18 months plus royalties on sales for 10 years for full rights to Hexalen altretamine, a second line treatment for ovarian cancer. Hexalen, which MEDI hasn't been ...